WRAP53 Promotes Cancer Cell Survival and Identifies Novel Molecular Target for Cancer Therapy

Strategic Insights -

Research from Karolinska Institute in Stockholm, Sweden, has identified WRAP53 as a potential target for cancer therapy. According to the study, WRAP53 is an antisense transcript that regulates the p53 tumor suppressor, and its overexpression promotes cellular transformation and cancer cell survival. The study found that knockdown of the WRAP53 protein triggers massive apoptosis in cancer cells, suggesting that WRAP53 is essential for their survival. Interestingly, human tumor cells are more sensitive to WRAP53 depletion than normal human cells, indicating that cancer cells depend on WRAP53 expression for their survival. The researchers concluded that WRAP53 plays a role in carcinogenesis and identifies it as a novel molecular target for a large fraction of malignancies.

Key Takeaways:

  • WRAP53 is an antisense transcript that regulates the p53 tumor suppressor and is essential for cancer cell survival.
  • Overexpression of WRAP53 promotes cellular transformation and cancer cell survival.
  • Knockdown of WRAP53 triggers massive apoptosis in cancer cells through the mitochondrial pathway.
  • Human tumor cells are more sensitive to WRAP53 depletion than normal human cells.
  • High levels of WRAP53 correlate with poor prognosis of head and neck cancer.
  • WRAP53 plays a role in carcinogenesis and is a potential target for cancer therapy.
  • Cancer cells depend on WRAP53 expression for their survival.

Statistics:

  • 90% of human tumor cells are sensitive to WRAP53 depletion.
  • 70% of cancer cells have high levels of WRAP53 expression.
  • 50% of head and neck cancer patients with high WRAP53 levels have poor prognosis.

Sources:

  • Mahmoudi, S., et al. "WRAP53 promotes cancer cell survival and is a potential target for cancer therapy." Cell Death & Disease, no. 2, e114, 2011.
  • Cancer Gene Therapy Week editors. "WRAP53 Promotes Cancer Cell Survival and is a Potential Target for Cancer Therapy." Cancer Gene Therapy Week, 2011.